CN116159101A - Traditional Chinese medicine composition and preparation method and application thereof - Google Patents
Traditional Chinese medicine composition and preparation method and application thereof Download PDFInfo
- Publication number
- CN116159101A CN116159101A CN202211651320.4A CN202211651320A CN116159101A CN 116159101 A CN116159101 A CN 116159101A CN 202211651320 A CN202211651320 A CN 202211651320A CN 116159101 A CN116159101 A CN 116159101A
- Authority
- CN
- China
- Prior art keywords
- alcohol
- concentrating
- alkaline hydrolysis
- water
- tenuifolin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 title claims abstract description 26
- 239000000843 powder Substances 0.000 claims abstract description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 78
- 235000019441 ethanol Nutrition 0.000 claims description 54
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 45
- 238000005904 alkaline hydrolysis reaction Methods 0.000 claims description 41
- 238000001556 precipitation Methods 0.000 claims description 40
- 238000001035 drying Methods 0.000 claims description 33
- 239000000463 material Substances 0.000 claims description 32
- DBJLNNAUDGIUAE-YGIRLYIESA-N (2s,3r,4s,4ar,6ar,6br,8as,12as,14ar,14br)-2-hydroxy-6b-(hydroxymethyl)-4,6a,11,11,14b-pentamethyl-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4,8a-dicarboxylic acid Chemical compound O([C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@]1(C)C(O)=O)C)(CO)CC[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DBJLNNAUDGIUAE-YGIRLYIESA-N 0.000 claims description 31
- 239000000284 extract Substances 0.000 claims description 31
- 229930182494 ginsenoside Natural products 0.000 claims description 31
- 229940089161 ginsenoside Drugs 0.000 claims description 31
- FKKZBCYPCGDQKZ-UHFFFAOYSA-N tenuifolin Natural products CC1(C)CCC2(CCC3(O)C(=CCC4C5(C)CC(O)C(OC6OC(CO)C(O)C(O)C6O)C(C)(C5CCC34C)C(=O)O)C2C1)C(=O)O FKKZBCYPCGDQKZ-UHFFFAOYSA-N 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 238000002156 mixing Methods 0.000 claims description 28
- 150000007949 saponins Chemical class 0.000 claims description 26
- 238000005303 weighing Methods 0.000 claims description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 24
- 239000000741 silica gel Substances 0.000 claims description 24
- 229910002027 silica gel Inorganic materials 0.000 claims description 24
- 229930182490 saponin Natural products 0.000 claims description 23
- 235000017709 saponins Nutrition 0.000 claims description 23
- 239000000706 filtrate Substances 0.000 claims description 22
- 239000003651 drinking water Substances 0.000 claims description 20
- 235000020188 drinking water Nutrition 0.000 claims description 20
- 244000197580 Poria cocos Species 0.000 claims description 19
- 235000008599 Poria cocos Nutrition 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 19
- 238000001291 vacuum drying Methods 0.000 claims description 18
- 239000000376 reactant Substances 0.000 claims description 16
- 238000003809 water extraction Methods 0.000 claims description 16
- 238000001914 filtration Methods 0.000 claims description 13
- 241000208340 Araliaceae Species 0.000 claims description 12
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 12
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 12
- 235000008434 ginseng Nutrition 0.000 claims description 12
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 230000001105 regulatory effect Effects 0.000 claims description 9
- 229910000831 Steel Inorganic materials 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 8
- 238000001704 evaporation Methods 0.000 claims description 8
- 239000010959 steel Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 4
- 238000002425 crystallisation Methods 0.000 claims description 4
- 230000008025 crystallization Effects 0.000 claims description 4
- 238000009826 distribution Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 238000004062 sedimentation Methods 0.000 claims description 4
- CCDRPBGPIXPGRW-JNKODXNQSA-N (4as,6ar,6as,6br,8ar,9r,10s,12ar,14bs)-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-10-[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical group O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(CO)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)C1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CCDRPBGPIXPGRW-JNKODXNQSA-N 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 3
- 229940048730 senega Drugs 0.000 claims description 3
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical group C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 claims description 2
- SWQINCWATANGKN-UHFFFAOYSA-N protopanaxadiol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC1C3(C)CCC(O)C(C)(C)C3CCC21C SWQINCWATANGKN-UHFFFAOYSA-N 0.000 claims description 2
- SHCBCKBYTHZQGZ-DLHMIPLTSA-N protopanaxatriol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-DLHMIPLTSA-N 0.000 claims description 2
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 241000245654 Gladiolus Species 0.000 claims 1
- 210000000081 body of the sternum Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 21
- 241001465754 Metazoa Species 0.000 abstract description 19
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract description 11
- 230000009182 swimming Effects 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 6
- 239000000725 suspension Substances 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 21
- 239000000243 solution Substances 0.000 description 17
- 239000002689 soil Substances 0.000 description 14
- 241001080798 Polygala tenuifolia Species 0.000 description 12
- 235000011121 sodium hydroxide Nutrition 0.000 description 12
- 238000012360 testing method Methods 0.000 description 8
- 240000006711 Pistacia vera Species 0.000 description 7
- 235000003447 Pistacia vera Nutrition 0.000 description 7
- 235000020233 pistachio Nutrition 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 208000019901 Anxiety disease Diseases 0.000 description 6
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 6
- 210000005036 nerve Anatomy 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 240000009022 Smilax rotundifolia Species 0.000 description 5
- 235000003205 Smilax rotundifolia Nutrition 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000020401 Depressive disease Diseases 0.000 description 3
- 229930182432 Polygalasaponin Natural products 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 230000003001 depressive effect Effects 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- PALNVYHUKHRDOP-UHFFFAOYSA-N UNPD162310 Natural products COC(=O)C1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(OC7OC(CO)C(O)C(O)C7O)C6O)C(C)(C)C5CCC34C)C2C1)C(=O)O PALNVYHUKHRDOP-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002898 effect on depression Effects 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 230000037308 hair color Effects 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- 244000205574 Acorus calamus Species 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 235000011996 Calamus deerratus Nutrition 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition, and a preparation method and application thereof. In order to improve the quality, stability, safety and effectiveness of the traditional Chinese medicine prescription, the invention provides a traditional Chinese medicine composition with a therapeutic effect on depression on the basis of classical prescription yippee powder, and provides a preparation method of the composition, and animal experiment results show that: the composition provided by the invention can obviously shorten the forced swimming immobility time and tail suspension immobility time of a depression model mouse, and can obviously prolong the times and the time percentage of the mouse entering an open arm. The composition provided by the invention has a significantly better effect than classical prescription Happy powder in the aspect of treating depression patients, has significantly reduced toxic and side effects, and has important development and application values.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition, and a preparation method and application thereof.
Background
The classical prescription Happy powder consists of polygala tenuifolia, ginseng, poria cocos and grassleaf sweelflag rhizome, is a representative prescription for tonifying qi and nourishing heart, soothing nerves and stabilizing mind, and is mainly used for treating heart qi deficiency, restlessness, amnesia and insomnia, heart shAN_SNe and the like, which is originally seen in the fourteenth volume (small intestine Fu) of Sunshan Ji Qianjin Fang (Confucius of first-aid). Wherein ginseng has the functions of invigorating primordial qi, soothing nerves and tonifying qi, and poria cocos has the functions of strengthening spleen and reducing phlegm, calming heart and soothing nerves, and promoting diuresis and removing dampness as auxiliary materials; rhizoma Acori Graminei has effects of resolving phlegm, inducing resuscitation, nourishing viscera, and refreshing; polygala tenuifolia calms the heart and tranquilizes the mind, eliminates phlegm and opens orifices, and can be combined with calamus to strengthen the effect of eliminating phlegm and opening orifices, and poria cocos to calm the heart and kidney and calm the nerves and promote intelligence. The four medicines have mild medicine properties and have the effects of nourishing the heart, soothing the nerves and improving the intelligence, and the medicine selection is accurate; the whole formula is mainly used for tonifying, strengthening middle-jiao and reducing diarrhea, simultaneously has the effects of resolving phlegm and inducing resuscitation, has strict compatibility, treats the traditional Chinese medical emotional diseases such as heart qi deficiency, restlessness, anxiety, insomnia, depression and severe palpitation, is similar to the depression of Western medicine, and is a basic prescription for improving intelligence, nourishing heart and soothing nerves and stabilizing mind in traditional Chinese medicine.
Anxiety and depressive disorders are mental diseases that seriously threaten the health of people, and recent research data indicate that the incidence rate of anxiety disorders in the elderly is as high as 10%, the incidence rate of anxiety disorders in the general population is also as high as 2% -5%, the incidence rate of depression in the young is about 2%, and the incidence rate of anxiety disorders is gradually increasing with the age. Most patients have anxiety and depression co-morbid conditions. At present, western medicines are still mainly used for treating depression, and the western medicines are from a single target point, so that the defects of narrow anti-depression spectrum, slow onset of action and large side effect are commonly existed. The traditional Chinese medicine has the characteristics of multiple components, small toxic and side effects, multiple effects, strong synergistic effect and overall regulation, and has unique advantages in the treatment of depression. However, due to the limitations of the complexity, scientific and technical conditions, research ideas, methods and other factors of the traditional Chinese medicine, the quality, stability, safety and effectiveness of the traditional Chinese medicine composition cannot be ensured. This becomes a key constraint factor for the traditional Chinese medicine to exert the effect of treating diseases.
Disclosure of Invention
In order to solve the problems of stability, safety, effectiveness and the like of the traditional Chinese medicine prescription (Happy powder) when being used for treating diseases, the invention takes the traditional Chinese medicine prescription compatibility and the theory related to prescription symptoms as guidance, and based on the internal relation of 'components-drug effects', the effective component group in the traditional Chinese medicine prescription preparation is determined by separating and extracting natural products and carrying out a series of pharmacodynamic screening and safety evaluation, and the traditional Chinese medicine composition with the prevention and treatment effect on depression is provided, and comprises the following four active components: ginsenoside, tenuifolin, rhizoma acori graminei water extraction and alcohol precipitation liquid and poria cocos micropowder.
Wherein the ginsenoside is protopanaxadiol and protopanaxatriol.
The active ingredients are as follows according to weight percent:
1-10 parts of ginsenoside and 1-10 parts of tenuifolin
10-100 parts of rhizoma acori graminei water extraction and alcohol precipitation liquid and 200-2000 parts of poria cocos micropowder
Preferably, it is:
ginsenoside 3 parts and senega saponin 2 parts
40 parts of glabrous greenbrier rhizome water extraction and alcohol precipitation liquid and 1200 parts of poria cocos micropowder
The preparation method of each component in the composition comprises the following steps:
the preparation method of the ginsenoside comprises the following steps:
(1) Alkaline hydrolysis reaction
Weighing total saponins of ginseng stem and leaf, and weighing total saponins (g) of ginseng stem and leaf: adding sodium hydroxide into the mixture according to the weight ratio of 1:1-1:4 of sodium hydroxide (g), adding small steel mill powder, uniformly mixing, transferring to a vacuum drying oven, reacting for 4-24h at the normal pressure of 100-240 ℃ to obtain an alkaline hydrolysis reactant, standing and cooling;
(2) Silica gel mixing material
Weighing silica gel with the total amount of 2-10 times, adding 630-4410 ml of absolute ethyl alcohol, uniformly stirring with the alkaline hydrolysis reactant obtained in the step (1), and naturally airing or evaporating in a vacuum rotary manner;
(3) Extraction of
Adding ethyl acetate (ml) into the silica gel stirring material in the step (2) according to the amount of 1:5-1:20, reflux-extracting for 1h at 80 ℃ for 2 times, and mixing to obtain a total extract;
(4) Concentrating and drying
Concentrating the extract obtained in the step (3) under reduced pressure to dryness, and drying in a vacuum drying oven to obtain the ginsenoside extract.
Preferably:
the preparation method of the ginsenoside comprises the following steps:
(1) Alkaline hydrolysis reaction
Weighing total saponins of ginseng stem and leaf, adding sodium hydroxide with the weight being 2 times that of the total saponins, adding small steel mill powder, uniformly mixing, transferring to a vacuum drying oven, setting the temperature at 170 ℃ at normal pressure, reacting for 12 hours to obtain alkaline hydrolysis reactants, standing and cooling;
(2) Silica gel mixing material
Weighing silica gel 7 times of the total amount of the materials, adding 2000ml of absolute ethyl alcohol, uniformly stirring with the alkaline hydrolysis reactant obtained in the step (1), and naturally airing or evaporating in a vacuum rotary manner;
(3) Extraction of
Adding ethyl acetate (ml) into the silica gel mixture in the step (2) according to the amount of 1:7, reflux-extracting for 1h at 80 ℃ for 2 times, and mixing to obtain a total extract;
(4) Concentrating and drying
Concentrating the extract obtained in the step (3) under reduced pressure to dryness, and drying in a vacuum drying oven to obtain the ginsenoside extract. The preparation method of the tenuifolin comprises the following steps:
(1) Decocting and extracting with water: weighing radix Polygalae, extracting with drinking water, mixing the water extracts, and concentrating to obtain concentrated solution;
(2) Alkaline hydrolysis: adding alkali into the concentrated solution for alkaline hydrolysis to obtain alkaline hydrolysis solution;
(3) Alcohol precipitation: adjusting the pH of the alkaline hydrolysis solution obtained in the step (2) to 4-5 by using acid, adjusting the alcohol degree to 70-90% by using absolute ethyl alcohol, filtering, and collecting filtrate;
(4) And (3) water sedimentation: concentrating the filtrate collected in the step (3) until no alcohol smell exists, adding drinking water for water precipitation, centrifugally collecting a precipitation part, and drying to obtain a crude tenuifolin;
(5) And (3) crystallization: recrystallizing the crude tenuifolin obtained in the step (4) to obtain tenuifolin.
Preferably:
the preparation method of the tenuifolin comprises the following steps:
(1) Decocting and extracting with water: weighing radix Polygalae, adding 10 times of drinking water, extracting for 3 times and 4 hr each time, mixing the water extractive solutions, and concentrating to obtain concentrated solution;
(2) Alkaline hydrolysis: adding alkali into the concentrated solution obtained in the step (1) until the concentration is 10%, and performing alkaline hydrolysis for 3 hours to obtain alkaline hydrolysis solution;
(3) Alcohol precipitation: and (3) regulating the pH value of the alkaline hydrolysis liquid obtained in the step (2) to 4-5 by using concentrated hydrochloric acid. Regulating alcohol degree to 70-90% with absolute ethyl alcohol, filtering and collecting filtrate;
(4) And (3) water sedimentation: concentrating the filtrate collected in the step (3) until no alcohol smell exists, adding 40L of drinking water into each kilogram of medicinal material for water precipitation, centrifugally collecting a precipitation part, and drying to obtain a crude tenuifolin;
(5) And (3) crystallization: reflux-recrystallizing the crude tenuifolin obtained in the step (4) with absolute ethanol to obtain tenuifolin.
The preparation method of the water extraction and alcohol precipitation solution of the grassleaf sweelflag rhizome comprises the following steps:
(1) Extraction of
Weighing 200g of rhizoma acori graminei decoction pieces, adding 10 times of drinking water for 2L, reflux-extracting for 2h, extracting for 2 times, and merging the extracting solutions after the extraction is finished;
(2) Concentrating
Concentrating the extract obtained in step (1) to about 0.5g/ml;
(3) Alcohol precipitation
Regulating the concentrated solution obtained in the step (2) to 70% of alcohol by using edible alcohol, and precipitating the alcohol overnight to obtain an alcohol precipitation solution;
(4) Filtration
Filtering the alcohol precipitation liquid obtained in the step (3), and reserving filtrate.
(5) Concentrating and drying
Concentrating the filtrate obtained in the step (4) under reduced pressure, drying to obtain rhizoma Acori Graminei extract, and drying in a vacuum drying oven.
The preparation method of the poria cocos micro powder comprises the following steps:
(1) Washing Poria with water, drying in oven at 40-60deg.C, pulverizing in high speed pulverizer, and sieving with 80 mesh sieve to obtain Poria coarse powder.
(2) Pulverizing Poria coarse powder obtained in step (1) with jet mill under compressed air pressure of 0.4-0.6Kpa and feeding speed of 0.5-10kg/h to obtain Poria micropowder, and analyzing the particle size distribution of Poria micropowder with laser particle size distribution analyzer to obtain D90<20um.
The anti-depression effect research is carried out on the traditional Chinese medicine composition, and the experimental result shows that: the traditional Chinese medicine composition can obviously shorten the forced swimming immobility time and tail suspension immobility time of a depressive mouse, and each effective component in the composition has obvious synergistic effect when the antidepressant effect is exerted, and the effect of the composition on treating the depressive is obviously better than the treatment effect of classical famous prescription yippee powder on the depressive.
Toxicity test results show that: compared with the classical prescription Happy powder, the composition provided by the invention has obviously reduced toxicity, is mainly characterized by good animal general condition, and obviously reduces the incidence rate of gastrointestinal bleeding and the death rate of animals.
The composition can be prepared into a pharmaceutical preparation, and the pharmaceutical preparation can contain pharmaceutically acceptable auxiliary materials besides the composition provided by the invention.
The pharmaceutical formulations include, but are not limited to, tablets, capsules, granules or pills.
The composition provided by the invention has the following advantages in treating depression:
1. compared with the classical prescription Happy powder, the traditional Chinese medicine powder has the advantages of enriching effective active ingredients, improving the bioavailability of medicinal substances and remarkably enhancing the treatment effect on depression.
2. The components are controllable, the toxic and side effects are less, and the components have obvious synergistic effect when treating depression.
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
In order for those skilled in the art to fully understand the present invention, the present invention is further illustrated by the following specific examples, but those skilled in the art should understand that the present invention is not limited in any way.
Preparation of ginsenoside example 1
(1) Alkaline hydrolysis reaction
Weighing total saponins of ginseng stem and leaf, adding sodium hydroxide with the weight being 2 times that of the total saponins, adding small steel mill powder, uniformly mixing, transferring to a vacuum drying oven, setting the temperature at 170 ℃ at normal pressure, reacting for 12 hours to obtain alkaline hydrolysis reactants, standing and cooling;
(2) Silica gel mixing material
Weighing silica gel 7 times of the total amount of the materials, adding 2000ml of absolute ethyl alcohol, uniformly stirring with the alkaline hydrolysis reactant obtained in the step (1), and naturally airing or evaporating in a vacuum rotary manner;
(3) Extraction of
Adding ethyl acetate (ml) into the silica gel mixture in the step (2) according to the amount of 1:7, reflux-extracting for 1h at 80 ℃ for 2 times, and mixing to obtain a total extract;
(4) Concentrating and drying
Concentrating the extract obtained in the step (3) under reduced pressure to dryness, and drying in a vacuum drying oven to obtain the ginsenoside extract.
Preparation of ginsenoside example 2
(1) Alkaline hydrolysis reaction
Weighing total saponins of ginseng stem and leaf, adding sodium hydroxide with the same weight, adding small steel mill powder, mixing uniformly, transferring to a vacuum drying oven, setting at normal pressure and reacting at 100 ℃ for 4 hours to obtain alkaline hydrolysis reactant, standing and cooling;
(2) Silica gel mixing material
Weighing silica gel with the total amount being 2 times that of the materials, adding 630ml of absolute ethyl alcohol, uniformly stirring with the alkaline hydrolysis reactant obtained in the step (1), and naturally airing or evaporating in a vacuum rotary manner;
(3) Extraction of
Adding ethyl acetate (ml) into the silica gel mixture in the step (2) according to the amount of 1:5, reflux-extracting for 1h at 80 ℃ for 2 times, and mixing to obtain a total extract;
(4) Concentrating and drying
Concentrating the extract obtained in the step (3) under reduced pressure to dryness, and drying in a vacuum drying oven to obtain the ginsenoside extract.
Preparation of ginsenoside example 3
(1) Alkaline hydrolysis reaction
Weighing total saponins of ginseng stem and leaf, adding sodium hydroxide with the weight being 4 times that of the total saponins, adding small steel mill powder, uniformly mixing, transferring to a vacuum drying oven, setting 240 ℃ at normal pressure, reacting for 24 hours to obtain alkaline hydrolysis reactant, standing and cooling;
(2) Silica gel mixing material
Weighing silica gel 10 times of the total amount of the materials, adding 4410ml of absolute ethyl alcohol, uniformly stirring with the alkaline hydrolysis reactant obtained in the step (1), and naturally airing or evaporating in a vacuum rotary manner;
(3) Extraction of
Adding ethyl acetate (ml) into the silica gel mixture in the step (2) according to the amount of 1:20, reflux-extracting for 1h at 80 ℃ for 2 times, and mixing to obtain a total extract;
(4) Concentrating and drying
Concentrating the extract obtained in the step (3) under reduced pressure to dryness, and drying in a vacuum drying oven to obtain the ginsenoside extract.
Preparation of ginsenoside example 4
(1) Alkaline hydrolysis reaction
Weighing total saponins of ginseng stem and leaf, adding sodium hydroxide with the weight being 2 times that of the total saponins, adding small steel mill powder, uniformly mixing, transferring to a vacuum drying oven, setting 240 ℃ at normal pressure, reacting for 12 hours to obtain alkaline hydrolysis reactant, standing and cooling;
(2) Silica gel mixing material
Weighing silica gel 10 times of the total amount of the materials, adding 3000ml of absolute ethyl alcohol, uniformly stirring with the alkaline hydrolysis reactant obtained in the step (1), and naturally airing or evaporating in a vacuum rotary manner;
(3) Extraction of
Adding ethyl acetate (ml) into the silica gel mixture in the step (2) according to the amount of 1:7, reflux-extracting for 1h at 80 ℃ for 2 times, and mixing to obtain a total extract;
(4) Concentrating and drying
Concentrating the extract obtained in the step (3) under reduced pressure to dryness, and drying in a vacuum drying oven to obtain the ginsenoside extract.
Preparation of tenuifolin example 1
Taking polygala tenuifolia medicinal materials, adding 10 times of drinking water into the medicinal materials, heating, refluxing and extracting for 4 hours, extracting for 3 times, merging and concentrating the extracting solution into clear paste, adding caustic soda flakes, regulating the pH to be 4.40 by using concentrated hydrochloric acid, regulating the alcohol degree to be 80 percent by adding absolute ethanol, filtering, collecting filtrate, concentrating the filtrate until the alcohol taste is not generated (the alcohol degree is 0), adding 40L of drinking water into each kilogram of medicinal materials for water precipitation, centrifuging and collecting a precipitated part, drying to obtain crude polygala tenuifolia saponins, adding absolute ethanol, repeatedly refluxing and recrystallizing to obtain the polygala tenuifolia saponins.
Preparation example 2 of tenuifolin
Taking polygala tenuifolia medicinal materials, adding 15 times of drinking water into the medicinal materials, heating, refluxing and extracting for 2 hours, extracting for 2 times, merging and concentrating the extracting solution into clear paste, adding caustic soda, adjusting the pH to be 4.85 by phosphoric acid, adding absolute ethanol to adjust the alcohol degree to be 70 percent, filtering, collecting filtrate, concentrating the filtrate until the alcohol smell is not generated (the alcohol degree is 0), adding 25L of drinking water into each kilogram of medicinal materials for water precipitation, centrifuging and collecting a precipitated part, drying to obtain crude tenuifolin, adding methanol, repeatedly refluxing and recrystallizing to obtain the tenuifolin.
Preparation example 3 of tenuifolin
Heating and reflux-extracting radix Polygalae with 10 times of drinking water for 1 hr, extracting for 1 time, concentrating the extractive solution to obtain fluid extract, adding caustic soda, adjusting to 10%, alkaline hydrolyzing for 1 hr, adjusting p H =4.30 with acetic acid, adding absolute ethanol to adjust alcohol degree to 80%, filtering, collecting filtrate, concentrating filtrate to no alcohol taste (alcohol degree of 0), adding 25L of drinking water per kilogram of medicinal material, precipitating with water, centrifuging, collecting precipitate, drying to obtain crude fine leaf radix Polygalae saponin, adding absolute ethanol, repeatedly reflux-crystallizing to obtain fine leaf radix Polygalae saponin.
Preparation example 4 of tenuifolin
Taking polygala tenuifolia medicinal materials, adding 20 times of drinking water into the medicinal materials, heating and reflux-extracting for 2 hours, extracting for 2 times, merging and concentrating the extracting solution to obtain clear paste, adding caustic soda, adjusting to 1%, alkaline hydrolysis for 3 hours, adjusting p H =4.0 by using concentrated hydrochloric acid, adding absolute ethyl alcohol to adjust the alcohol degree to 90%, filtering, collecting filtrate, concentrating the filtrate to be free of alcohol taste (alcohol degree is 0), adding 25L of drinking water into each kilogram of medicinal materials for water precipitation, centrifugally collecting a precipitation part, drying to obtain crude polygala tenuifolia saponins, adding absolute ethyl alcohol, repeatedly refluxing and recrystallizing to obtain the polygala tenuifolia saponins.
Preparation example 5 of tenuifolin
Taking polygala tenuifolia medicinal materials, adding 20 times of drinking water into the medicinal materials, heating, refluxing and extracting for 2 hours, extracting for 2 times, merging and concentrating the extracting solution into clear paste, adding caustic soda, adjusting to 5%, alkaline hydrolyzing for 2 hours, adjusting p H =5.0 by using concentrated hydrochloric acid, adding absolute ethyl alcohol to adjust the alcohol degree to 80%, filtering, collecting filtrate, concentrating the filtrate until the alcohol smell-free measured alcohol degree is 0, adding 30L of drinking water into each kilogram of medicinal materials for water precipitation, centrifugally collecting a precipitation part, drying to obtain crude polygala tenuifolia saponins, adding methanol, repeatedly refluxing and recrystallizing to obtain the polygala tenuifolia saponins.
Composition example 1
Ginsenoside 3 parts and senega saponin 2 parts
40 parts of glabrous greenbrier rhizome water extraction and alcohol precipitation liquid and 1200 parts of poria cocos micropowder
Composition example 2
1 part of ginsenoside and 1 part of tenuifolin
10 parts of glabrous greenbrier rhizome water extraction and alcohol precipitation liquid and 200 parts of poria cocos micro powder
Composition example 3
10 parts of ginsengenin and 10 parts of tenuifolin
100 parts of glabrous greenbrier rhizome water extraction and alcohol precipitation liquid and 2000 parts of poria cocos micropowder
Composition example 4
5 parts of ginsenoside and 5 parts of tenuifolin
100 parts of glabrous greenbrier rhizome water extraction and alcohol precipitation liquid and 2000 parts of poria cocos micropowder
Examples of pharmaceutical effects of the compositions
Therapeutic effect of composition on depression model mice
1. Animal modeling and grouping
2.100 Kunming mice, copying depression model by forced swimming experiment, selecting 84 mice with successful model, and randomly dividing into 7 groups, namely model group, pistachio group, ginsenoside group, tenuifolia saponin group, rhizoma Acori Graminei water extraction and alcohol precipitation liquid group, poria micropowder group and composition group (composition example 1). Methods of administration and dosage
Happy powder group (each traditional Chinese medicine in the classical famous prescription Happy powder is crushed into powder by a high-speed crusher), and the dosage of administration is 960mg/kg
Ginsenoside group, and administration dosage is 1.5mg/kg
Polygalasaponin group with administration dosage of 1.0mg/kg
Rhizoma Acori Graminei water extraction and alcohol precipitation liquid group, and administration dosage is 20mg/kg
Poria cocos micropowder group, and administration dosage is 600mg/kg
Composition group, administration dose 622.5mg/kg
The administration volume of each group was 30ml/kg, and the model group was administered with an equal volume of physiological saline.
Each group of mice was continuously administrated by gastric lavage for two weeks according to the above dose and administration volume, after the last administration, clear water was poured into a bucket (diameter: 30cm, height: 60 cm), water depth: 40cm, water temperature: 25.+ -. 2) degree centigrade, and after the mice were put into water to be adapted for 2min, swimming immobility time within 4min was measured and accumulated. The time when the mouse body was slightly curled but kept in a hanging posture and the nostrils were exposed to the water surface was recorded as the immobile time. After the experiment of each mouse is finished, the mice are wiped dry by a towel and dried by a blower.
3. Overhead maze test
3.1 Experimental methods
The experimental mice were observed for behavioral changes using an overhead plus maze. The inner wall and the bottom surface of the overhead cross maze are dark gray, have a height of 50cm from the ground, and are formed by two opposite open arms (open arm, length x width is 45cmx15 cm), two opposite closed arms (closed arm, length x width x height is 45cm x15cm x 30cm) and a central platform (15 cmx15 cm) for connecting the four arms in a cross shape. The top of the closed arm is open and is carried out under the quiet and shading conditions. Before EPM test, the mice to be tested are placed in a squirrel cage, and after 5min of free exploration, the mice are quickly placed at the central platform of the EPM, so that the heads of the mice are opposite to any one of the open arms, and after release, the mice begin to observe the test. Each rat was tested for 5min. After the mice are taken out, the bottoms of the cases are thoroughly wiped by dipping the towels with clean water and low-concentration alcohol, and the mice are waited for volatilizing and diffusing, so that the phenomenon that odor is remained to interfere the observation result of the next mouse is avoided.
3.2 observations index
(1) Open arm entry (OE); (2) open arm dwell time (OT); (3) number of closed arm entries (CE); (4) closed arm dwell time (CT); counting the total number of entries (oe+ce) into the open and closed arms; the proportion of times of entering the open arms; open arm residence time ratio.
4. Tail suspension experiment
After the last stomach infusion, the tail part of the mouse is fixed on the edge of the rack by using the adhesive tape, so that the tail part of the mouse is in a reverse hanging state, the head part is about 5cm away from the table top, and the mice are kept at a certain distance to avoid mutual interference. After hanging the mice for 2min, observations were started for 4min, and the time(s) of immobility (stop struggling in air or only fine limb movements) of the mice was accumulated for 4 min.
5. Statistical analysis
The single-factor analysis of variance of the F test was performed using SPSS 17.0 software.
6. Experimental results
6.1 forced swimming test results
Table 1 comparison of forced swimming immobility time in groups of depressed mice
| Group of | n | Swimming immobility time(s) |
| Model group | 12 | 232.12 soil 22.13 |
| Happy powder group | 12 | 180.24 soil 24.12 # |
| Ginsenoside group | 12 | 191.56 soil 19.07 # |
| Polygalasaponin group of tenuifolia | 12 | 199.27 soil 21.08 # |
| Water extraction and alcohol precipitation liquid group of grassleaf sweelflag rhizome | 12 | 201.19 soil 18.92 # |
| Poria cocos micropowder group | 12 | 194.45 soil 17.01 # |
| Composition set | 12 | 159.27 soil 14.89 #﹩ |
Each of the administration groups was compared with the model group, # p<0.05; compared with the yippee powder and each individual component, ﹩ p<0.05。
the results show that the time for forced swimming of mice in each administration group is obviously shortened compared with a model group, wherein the time of the composition group provided by the invention is obviously shortened, and compared with a pistachio powder group and each individual component in the composition, the composition provided by the invention has obvious difference (p < 0.05), and the results show that compared with the traditional pistachio powder, the composition provided by the invention has more obvious effect on improving the depression emotion of depression patients.
6.2 elevated plus maze test results
Table 2 percent open arm number and percent open time for each group of model mice with depression
Each of the administration groups was compared with the model group, # p<0.05; compared with the yippee powder and each individual component, ﹩ p<0.05。
the results show that compared with a model group, the number and time percentage of mice entering an open arm of each administration group are obviously prolonged, wherein the composition provided by the invention has the most obvious prolonged action, and compared with a pistachio powder group and each individual component in the composition, the composition provided by the invention has obvious difference (p < 0.05), and the results show that compared with classical pistachio powder, the composition provided by the invention has obviously improved effect on the treatment of depression patients, and each component in the composition has obvious synergistic action.
6.3 tail suspension test
TABLE 3 Effect of compositions on mice tail-holding time
| Group of | n | Time of immobility(s) within 4min |
| Model group | 12 | 121.90 soil 12.18 |
| Happy powder group | 12 | 80.94 soil 14.62 # |
| Ginsenoside group | 12 | 101.35 soil 19.14 # |
| Polygalasaponin group of tenuifolia | 12 | 99.38 soil 21.09 # |
| Water extraction and alcohol precipitation liquid group of grassleaf sweelflag rhizome | 12 | 101.33 soil 18.17 # |
| Poria cocos micropowder group | 12 | 94.38 soil 17.22 # |
| Composition set | 12 | 59.47 soil 14.39 #﹩ |
Each administration group was compared with the model group， # p<0.05; compared with the yippee powder and each individual component, ﹩ p<0.05。
the results show that compared with a model group, the tail suspension time of mice in each administration group is obviously shortened, wherein the time of the composition group provided by the invention is obviously shortened, and compared with a pistachio powder group and each single component in the composition, the composition provided by the invention has obvious difference (p < 0.05), and the results show that compared with the traditional pistachio powder, the composition provided by the invention has more obvious effect on improving the depression emotion of depression patients.
The pharmacodynamic test of the compositions in composition examples 1-4 is carried out by using the experimental method in the pharmacodynamic example, and the results show that the treatment effect of each composition in composition examples 1-4 on depression is obviously better than that of the classical Happy powder.
Toxicity test
1. Experimental animal
| Animal strain | ICR mice |
| Sex (sex) | Male male |
| Body weight/age range | 27-30 g/5 weeks |
| Quantity of | 30 pieces of |
| Suppliers (suppliers) | Experimental animals Breeding Limited for Jinan Pengyue |
| Producing license numbers | SCXK 20190003 |
| Use license number | SYXK 20180008 |
2. Grouping animals
Animals that were quarantined were randomly divided into open heart groups, low dose groups and high dose groups, and the amounts and frequency of administration of each group are shown in table 4:
TABLE 4 grouping and dosing of animals
Animals of each group were dosed continuously for four weeks according to the routes of administration indicated in the table above.
3. Observation index
3.1 general Condition observations
Daily observations and recordings of animal activity, hair color, stool and urine, abdominal distension and weighing were made during the course of administration.
3.2 gastrointestinal bleeding and death of animals
Animals were anesthetized and dissected after the last administration, gastrointestinal bleeding was observed, and mortality was counted for each group.
4. Experimental results
4.1 general Condition observations
The free-ranging mice have obviously reduced activity, dark hair color, abdominal distension, thin stool, bloody stool and the like, but the composition provided by the invention has few of the above adverse conditions, most animals are normal, and the weight of the free-ranging animals is obviously lower than that of the animals in the composition provided by the invention.
4.2 gastrointestinal bleeding and death of animals
The number of gastrointestinal bleeding occurring in animals of the composition group provided by the invention is obviously smaller than that of the Happy powder group, and no death phenomenon of animals occurs, and the specific results are shown in Table 5.
Table 5 comparison of gastrointestinal bleeding and animal death in groups of animals
Claims (6)
1. A Chinese medicinal composition is characterized in that the active ingredients of the Chinese medicinal composition comprise ginsenoside, tenuifolin, rhizoma acori graminei water extraction and alcohol precipitation liquid and poria cocos micropowder.
2. The composition of claim 1, wherein the ginsenoside is protopanaxadiol or protopanaxatriol.
3. The traditional Chinese medicine composition according to claim 1, wherein the active ingredients are as follows in weight fraction: 1-10 parts of ginsenoside and 1-10 parts of tenuifolin
10-100 parts of rhizoma acori graminei water extraction and alcohol precipitation liquid and 200-2000 parts of poria cocos micropowder
Preferably, it is:
ginsenoside 3 parts and senega saponin 2 parts
40 parts of gladiolus water extraction and alcohol precipitation liquid and 1200 parts of poria cocos micropowder.
4. A method for preparing the traditional Chinese medicine composition of claims 1-3, characterized in that the method for preparing the ginsenoside comprises the following steps:
(1) Alkaline hydrolysis reaction
Weighing total saponins of ginseng stem and leaf, and weighing total saponins (g) of ginseng stem and leaf: adding sodium hydroxide into the mixture according to the weight ratio of 1:1-1:4 of sodium hydroxide (g), adding small steel mill powder, uniformly mixing, transferring to a vacuum drying oven, reacting for 4-24h at the normal pressure of 100-240 ℃ to obtain an alkaline hydrolysis reactant, standing and cooling;
(2) Silica gel mixing material
Weighing silica gel with the total amount of 2-10 times, adding 630-4410 ml of absolute ethyl alcohol, uniformly stirring with the alkaline hydrolysis reactant obtained in the step (1), and naturally airing or evaporating in a vacuum rotary manner;
(3) Extraction of
Adding ethyl acetate (ml) into the silica gel stirring material in the step (2) according to the amount of 1:5-1:20, reflux-extracting for 1h at 80 ℃ for 2 times, and mixing to obtain a total extract;
(4) Concentrating and drying
Concentrating the extract obtained in the step (3) under reduced pressure to dryness, and drying in a vacuum drying oven to obtain a ginsenoside extract;
the preparation method of the tenuifolin comprises the following steps:
(1) Decocting and extracting with water: weighing radix Polygalae, extracting with drinking water, mixing the water extracts, and concentrating to obtain concentrated solution;
(2) Alkaline hydrolysis: adding alkali into the concentrated solution for alkaline hydrolysis to obtain alkaline hydrolysis solution;
(3) Alcohol precipitation: adjusting the pH value of the alkaline hydrolysis liquid obtained in the step (2) to 4-5 by acid,
regulating alcohol degree to 70-90% with absolute ethyl alcohol, filtering and collecting filtrate;
(4) And (3) water sedimentation: concentrating the filtrate collected in the step (3) until no alcohol smell exists, adding drinking water for water precipitation, centrifugally collecting a precipitation part, and drying to obtain a crude tenuifolin;
(5) And (3) crystallization: recrystallizing the crude tenuifolin obtained in the step (4) to obtain tenuifolin;
the preparation method of the water extraction and alcohol precipitation solution of the grassleaf sweelflag rhizome comprises the following steps:
(1) Extraction of
Weighing 200g of rhizoma acori graminei decoction pieces, adding 10 times of drinking water for 2L, reflux-extracting for 2h, extracting for 2 times, and merging the extracting solutions after the extraction is finished;
(2) Concentrating
Concentrating the extract obtained in step (1) to about 0.5g/ml;
(3) Alcohol precipitation
Regulating the concentrated solution obtained in the step (2) to 70% of alcohol by using edible alcohol, and precipitating the alcohol overnight to obtain an alcohol precipitation solution;
(4) Filtration
Filtering the alcohol precipitation liquid obtained in the step (3), and reserving filtrate.
(5) Concentrating and drying
Concentrating the filtrate obtained in the step (4) under reduced pressure, drying to obtain rhizoma Acori Graminei extract, and drying in a vacuum drying oven.
The preparation method of the poria cocos micro powder comprises the following steps: the preparation method of the poria cocos micro powder comprises the following steps:
(1) Washing Poria with water, drying in oven at 40-60deg.C, pulverizing in high speed pulverizer, and sieving with 80 mesh sieve to obtain Poria coarse powder;
(2) Pulverizing Poria coarse powder obtained in step (1) with jet mill under compressed air pressure of 0.4-0.6Kpa and feeding speed of 0.5-10kg/h to obtain Poria micropowder, and analyzing the particle size distribution of Poria micropowder with laser particle size distribution analyzer.
5. The method of claim 4, wherein the method of preparing ginsenoside comprises the steps of:
(1) Alkaline hydrolysis reaction
Weighing total saponins of ginseng stem and leaf, adding sodium hydroxide with the weight being 2 times that of the total saponins, adding small steel mill powder, uniformly mixing, transferring to a vacuum drying oven, setting the temperature at 170 ℃ at normal pressure, reacting for 12 hours to obtain alkaline hydrolysis reactants, standing and cooling;
(2) Silica gel mixing material
Weighing silica gel 7 times of the total amount of the materials, adding 2000ml of absolute ethyl alcohol, uniformly stirring with the alkaline hydrolysis reactant obtained in the step (1), and naturally airing or evaporating in a vacuum rotary manner;
(3) Extraction of
Adding ethyl acetate (ml) into the silica gel mixture in the step (2) according to the amount of 1:7, reflux-extracting for 1h at 80 ℃ for 2 times, and mixing to obtain a total extract;
(4) Concentrating and drying
Concentrating the extract obtained in the step (3) under reduced pressure to dryness, and drying in a vacuum drying oven to obtain the ginsenoside extract.
6. The preparation method of the tenuifolin according to claim 4, wherein the preparation method of the tenuifolin comprises the following steps:
(1) Decocting and extracting with water: weighing radix Polygalae, adding 10 times of drinking water, extracting for 3 times and 4 hr each time, mixing the water extractive solutions, and concentrating to obtain concentrated solution;
(2) Alkaline hydrolysis: adding alkali into the concentrated solution obtained in the step (1) until the concentration is 10%, and performing alkaline hydrolysis for 3 hours to obtain alkaline hydrolysis solution;
(3) Alcohol precipitation: and (3) regulating the pH value of the alkaline hydrolysis liquid obtained in the step (2) to 4-5 by using concentrated hydrochloric acid. Regulating alcohol degree to 70-90% with absolute ethyl alcohol, filtering and collecting filtrate;
(4) And (3) water sedimentation: concentrating the filtrate collected in the step (3) until no alcohol smell exists, adding 40L of drinking water for water precipitation, centrifugally collecting a precipitation part, and drying to obtain a crude tenuifolin;
(5) And (3) crystallization: reflux-recrystallizing the crude tenuifolin obtained in the step (4) with absolute ethanol to obtain tenuifolin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211651320.4A CN116159101A (en) | 2020-06-24 | 2020-06-24 | Traditional Chinese medicine composition and preparation method and application thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010592383.1A CN111557992A (en) | 2020-06-24 | 2020-06-24 | Traditional Chinese medicine composition and preparation method and application thereof |
| CN202211651320.4A CN116159101A (en) | 2020-06-24 | 2020-06-24 | Traditional Chinese medicine composition and preparation method and application thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010592383.1A Division CN111557992A (en) | 2020-06-24 | 2020-06-24 | Traditional Chinese medicine composition and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116159101A true CN116159101A (en) | 2023-05-26 |
Family
ID=72071284
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211651320.4A Pending CN116159101A (en) | 2020-06-24 | 2020-06-24 | Traditional Chinese medicine composition and preparation method and application thereof |
| CN202010592383.1A Pending CN111557992A (en) | 2020-06-24 | 2020-06-24 | Traditional Chinese medicine composition and preparation method and application thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010592383.1A Pending CN111557992A (en) | 2020-06-24 | 2020-06-24 | Traditional Chinese medicine composition and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN116159101A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101062113A (en) * | 2006-04-25 | 2007-10-31 | 成都中医药大学 | Milkwort extract, its preparation method and application |
| CN101816766A (en) * | 2010-01-27 | 2010-09-01 | 蔡光先 | Chinese medicinal composition for treating tristimania |
| CN102180936A (en) * | 2011-03-28 | 2011-09-14 | 南京泽朗农业发展有限公司 | Method for extracting tenuifolin from polygala root |
| CN102311474A (en) * | 2010-07-07 | 2012-01-11 | 北京师范大学 | Method for preparing protopanaxadiol and protopanaxatriol by solvent-free method |
| CN102895432A (en) * | 2011-07-26 | 2013-01-30 | 王登之 | Prescription and preparation method of rejoicing powder having new dosage form |
| WO2013149470A1 (en) * | 2012-04-06 | 2013-10-10 | 北京大学 | Bisbenzylisoquinoline compound or pharmaceutically acceptable salt treatment and new application in easing depression symptom |
| CN104840527A (en) * | 2015-05-02 | 2015-08-19 | 浙江大学 | Composition containing tenuifoliside and ginsenoside |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101168024B (en) * | 2007-10-25 | 2010-12-01 | 北京星昊医药股份有限公司 | Proprietary Chinese medicine for treating depression and production method thereof |
| CN103965281B (en) * | 2013-01-31 | 2016-06-08 | 上海中药创新研究中心 | A kind of protopanoxadiol derivative, its preparation method and application thereof |
-
2020
- 2020-06-24 CN CN202211651320.4A patent/CN116159101A/en active Pending
- 2020-06-24 CN CN202010592383.1A patent/CN111557992A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101062113A (en) * | 2006-04-25 | 2007-10-31 | 成都中医药大学 | Milkwort extract, its preparation method and application |
| CN101816766A (en) * | 2010-01-27 | 2010-09-01 | 蔡光先 | Chinese medicinal composition for treating tristimania |
| CN102311474A (en) * | 2010-07-07 | 2012-01-11 | 北京师范大学 | Method for preparing protopanaxadiol and protopanaxatriol by solvent-free method |
| CN102180936A (en) * | 2011-03-28 | 2011-09-14 | 南京泽朗农业发展有限公司 | Method for extracting tenuifolin from polygala root |
| CN102895432A (en) * | 2011-07-26 | 2013-01-30 | 王登之 | Prescription and preparation method of rejoicing powder having new dosage form |
| WO2013149470A1 (en) * | 2012-04-06 | 2013-10-10 | 北京大学 | Bisbenzylisoquinoline compound or pharmaceutically acceptable salt treatment and new application in easing depression symptom |
| CN104840527A (en) * | 2015-05-02 | 2015-08-19 | 浙江大学 | Composition containing tenuifoliside and ginsenoside |
Non-Patent Citations (3)
| Title |
|---|
| LU XU，ET AL.: "UPLC-Q-TOF-MSE analysis of the constituents of Ding-Zhi-Xiao-Wan, a traditional Chinese antidepressant, in normal and depressive rats", JOURNAL OF CHROMATOGRAPHY B, vol. 1026, no. 2016, pages 282 - 283 * |
| 李明亚，等: "石菖蒲几种粗提取物的抗抑郁作用", 广东药学院学报, vol. 20, no. 02, pages 142 * |
| 桂卉，等: "超微粉碎对茯苓多糖溶出特性的影响", 时珍国医国药, vol. 20, no. 11, pages 2808 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111557992A (en) | 2020-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108042627B (en) | Composition for treating hyperuricemia and preparation method and application thereof | |
| CN106362020B (en) | A kind of pine pollen composition and preparation method thereof with improvement defecating feces excretion | |
| CN102319289B (en) | Hyperglycemic Chinese medicinal composition comprising cinnamon polyphenol and the like and preparation method of hyperglycemic Chinese medicinal composition | |
| CN102526353B (en) | A kind of preparation method for the treatment of the drug combination preparation of myocardial ischemia | |
| CN108785412B (en) | Composition with function of improving sleep and preparation method thereof | |
| JP2016160198A (en) | Kaempferia parviflora-containing compositions | |
| WO2021008265A1 (en) | Anti-aging soft capsule for menopausal women and preparation method therefor | |
| CN116159101A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN114470114B (en) | Application of Mailuoshutong preparation in preparation of medicine for treating constipation | |
| CN105943617A (en) | Application of whole hemp extract in preparation of anti-hepatitis drugs | |
| CN101584852B (en) | Pharmaceutical preparation for getting rid of phlegm and retained fluid | |
| WO2014134833A1 (en) | Edible composition, preparation method therefor, and food product comprising the composition | |
| CN104435298B (en) | A kind of medicine composition for treating depression | |
| CN107375509A (en) | It is a kind of to be used to improve immunity, the health food of pre- anti-cancer | |
| CN105935375A (en) | Application of Quanmasu in preparation of anti-aging drugs | |
| CN104055963B (en) | A kind of fat reducing Chinese medicine composition and preparation method | |
| CN107595870B (en) | Brain-strengthening and nerve-soothing pharmaceutical composition, pharmaceutical preparation, application and preparation method | |
| CN106074710A (en) | A kind of medicine treating epilepsy | |
| KR101054020B1 (en) | Composition for preventing and treating allergic diseases containing Camellia seed oil extract of longevity situation mushroom | |
| JP2007532493A (en) | Chinese medicine preparation for treating AIDS and preparation method thereof | |
| CN104886574B (en) | A kind of middle-aged and old health food for improving the health care of sleep protection eyesight and preparation method thereof | |
| CN108704036A (en) | A kind of Chinese traditional compound medicine and preparation method thereof for treating gout | |
| CN103800449B (en) | A kind of Chinese medicine composition for the treatment of Yin Xu Nei Re Zheng type 2 diabetes mellitus | |
| CN109549193A (en) | A kind of Chinese medicine compound prescription improves the health food and preparation method thereof of sleep | |
| CN110448622B (en) | Medicine for treating heat type cold and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |